A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC)
A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy (PACIFIC)
Sponsor: AstraZeneca
This PHASE3 trial investigates Non-Small Cell Lung Cancer and is currently completed. AstraZeneca leads this study, which shows 30 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
30 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Nov 2023 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Aug 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE3
▶ Show 25 earlier versions
-
May 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE3
-
Feb 2023 — May 2023 [monthly]
Active Not Recruiting PHASE3
-
Dec 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE3
-
Sep 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE3
-
May 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE3
-
Feb 2022 — May 2022 [monthly]
Active Not Recruiting PHASE3
-
Jan 2022 — Feb 2022 [monthly]
Active Not Recruiting PHASE3
-
Dec 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE3
-
Oct 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE3
-
Sep 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Apr 2020 — Oct 2020 [monthly]
Active Not Recruiting PHASE3
-
Jan 2020 — Apr 2020 [monthly]
Active Not Recruiting PHASE3
-
Oct 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE3
-
Jul 2019 — Oct 2019 [monthly]
Active Not Recruiting PHASE3
-
May 2019 — Jul 2019 [monthly]
Active Not Recruiting PHASE3
-
Feb 2019 — May 2019 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE3
-
Feb 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Jul 2017 — Feb 2018 [monthly]
Active Not Recruiting PHASE3
-
Jun 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE3
-
Mar 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Mar 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
May 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalst, Belgium , Adana, Turkey (Türkiye) , Alicante, Spain , Amsterdam, Netherlands , Ankara, Turkey (Türkiye) , Athens, Greece , Atlanta, United States , Austin, United States , Aviano, Italy , Avignon, France and 193 more locations